|
1
|
Chin LS, Ma L and DiBiase S: Radiation
necrosis following gamma knife surgery: a case-controlled
comparison of treatment parameters and long-term clinical follow
up. J Neurosurg. 94:899–904. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ali FS, Arevalo O, Zorofchian S, Patrizz
A, Riascos R, Tandon N, Blanco A, Ballester LY and Esquenazi Y:
Cerebral radiation necrosis: Incidence, pathogenesis, diagnostic
challenges, and future opportunities. Curr Oncol Rep. 21:662019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kotsarini C, Griffiths PD, Wilkinson ID
and Hoggard N: A systematic review of the literature on the effects
of dexamethasone on the brain from in vivo human-based studies:
Implications for physiological brain imaging of patients with
intracranial tumors. Neurosurgery. 67:1799–815; discussion 1815.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang X, Ren H and Fu J: Treatment of
radiation-induced brain necrosis. Oxid Med Cell Longev.
2021:47935172021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liao G, Khan M, Zhao Z, Arooj S, Yan M and
Li X: Bevacizumab treatment of radiation-induced brain necrosis: A
systematic review. Front Oncol. 11:5934492021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS: Toxicities of antiangiogenic
therapy in non-small-cell lung cancer. Clin Lung Cancer. 8 (Suppl
1):S23–S30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson DH, Fehrenbacher L, Novotny WF,
Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III,
Gaudreault J, Damico LA, et al: Randomized phase II trial comparing
bevacizumab plus carboplatin and paclitaxel with carboplatin and
paclitaxel alone in previously untreated locally advanced or
metastatic non-small-cell lung cancer. J Clin Oncol. 22:2184–2191.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hanna N, Johnson D, Temin S, Baker S Jr,
Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl
NB, et al: Systemic therapy for stage IV non-small-cell lung
cancer: American society of clinical oncology clinical practice
guideline update. J Clin Oncol. 35:3484–3515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martino A, Krainik A, Pasteris C, Hoffmann
D, Chabardes S, Berger F, Le Bas JF, Cantin S, Attye A and Grand S:
Neurological imaging of brain damages after radiotherapy and/or
chimiotherapy. J Neuroradiol. 41:52–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Le Rhun E, Dhermain F, Vogin G, Reyns N
and Metellus P: Radionecrosis after stereotactic radiotherapy for
brain metastases. Expert Rev Neurother. 16:903–914. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matuschek C, Bölke E, Nawatny J, Hoffmann
TK, Peiper M, Orth K, Gerber PA, Rusnak E, Lammering G and Budach
W: Bevacizumab as a treatment option for radiation-induced cerebral
necrosis. Strahlenther Onkol. 187:135–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheung MC, Chan AS, Law SC, Chan JH and
Tse VK: Impact of radionecrosis on cognitive dysfunction in
patients after radiotherapy for nasopharyngeal carcinoma. Cancer.
97:2019–2026. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang XS, Ying HM, He XY, Zhou ZR, Wu YR
and Hu CS: Treatment of cerebral radiation necrosis with nerve
growth factor: A prospective, randomized, controlled phase II
study. Radiother Oncol. 120:69–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang CL, Liu L, Li Z and Buttgereit F:
The novel strategy of glucocorticoid drug development via targeting
nongenomic mechanisms. Steroids. 102:27–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Y, Rong X, Hu W, Huang X, Li Y, Zheng
D, Cai Z, Zuo Z and Tang Y: Bevacizumab monotherapy reduces
radiation-induced brain necrosis in nasopharyngeal carcinoma
patients: A randomized controlled trial. Int J Radiat Oncol Biol
Phys. 101:1087–1095. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sadraei NH, Dahiya S, Chao ST, Murphy ES,
Osei-Boateng K, Xie H, Suh JH, Peereboom DM, Stevens GH and
Ahluwalia MS: Treatment of cerebral radiation necrosis with
bevacizumab: The cleveland clinic experience. Am J Clin Oncol.
38:304–310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhuang H, Yuan X, Zheng Y, Li X, Chang JY,
Wang J, Wang X, Yuan Z and Wang P: A study on the evaluation method
and recent clinical efficacy of bevacizumab on the treatment of
radiation cerebral necrosis. Sci Rep. 6:243642016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rahmathulla G, Marko NF and Weil RJ:
Cerebral radiation necrosis: A review of the pathobiology,
diagnosis and management considerations. J Clin Neurosci.
20:485–502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Remler MP, Marcussen WH and Tiller-Borsich
J: The late effects of radiation on the blood brain barrier. Int J
Radiat Oncol Biol Phys. 12:1965–1969. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Levin VA, Edwards MS and Byrd A:
Quantitative observations of the acute effects of X-irradiation on
brain capillary permeability: Part I. Int J Radiat Oncol Biol Phys.
5:1627–1631. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nonoguchi N, Miyatake SI, Fukumoto M,
Furuse M, Hiramatsu R, Kawabata S, Kuroiwa T, Tsuji M, Fukumoto M
and Ono K: The distribution of vascular endothelial growth
factor-producing cells in clinical radiation necrosis of the brain:
pathological consideration of their potential roles. J Neurooncol.
105:423–431. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoritsune E, Furuse M, Kuwabara H, Miyata
T, Nonoguchi N, Kawabata S, Hayasaki H, Kuroiwa T, Ono K, Shibayama
Y and Miyatake S: Inflammation as well as angiogenesis may
participate in the pathophysiology of brain radiation necrosis. J
Radiat Res. 55:803–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garcia J, Hurwitz HI, Sandler AB, Miles D,
Coleman RL, Deurloo R and Chinot OL: Bevacizumab
(Avastin®) in cancer treatment: A review of 15 years of
clinical experience and future outlook. Cancer Treat Rev.
86:1020172020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gonzalez J, Kumar AJ, Conrad CA and Levin
VA: Effect of bevacizumab on radiation necrosis of the brain. Int J
Radiat Oncol Biol Phys. 67:323–326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Torcuator R, Zuniga R, Mohan YS, Rock J,
Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M and
Mikkelsen T: Initial experience with bevacizumab treatment for
biopsy confirmed cerebral radiation necrosis. J Neurooncol.
94:63–68. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boothe D, Young R, Yamada Y, Prager A,
Chan T and Beal K: Bevacizumab as a treatment for radiation
necrosis of brain metastases post stereotactic radiosurgery. Neuro
Oncol. 15:1257–1263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng X, Zhao R, Wu S, Shen G, Ding L, Sun
B and Wang J: Efficacy of repeated low-dose bevacizumab treatment
with long-dosing interval for radiation-induced brain necrosis: A
case report. Cancer Biol Ther. 18:63–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alessandretti M, Buzaid AC, Brandão R and
Brandão EP: Low-dose bevacizumab is effective in radiation-induced
necrosis. Case Rep Oncol. 6:598–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Pan L, Sheng X, Mao Y, Yao Y, Wang
E, Zhang N and Dai J: Reversal of cerebral radiation necrosis with
bevacizumab treatment in 17 Chinese patients. Eur J Med Res.
17:252012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel
JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR and Jackson
EF: Randomized double-blind placebo-controlled trial of bevacizumab
therapy for radiation necrosis of the central nervous system. Int J
Radiat Oncol Biol Phys. 79:1487–1495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Remon J, Le Péchoux C, Caramella C,
Dhermain F, Louvel G, Soria JC and Besse B: Brain Radionecrosis
Treated with bevacizumab in a Patient with Resected squamous cell
carcinoma of the Lung. J Thorac Oncol. 12:e1–e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sandler AB, Schiller JH, Gray R, Dimery I,
Brahmer J, Samant M, Wang LI and Johnson DH: Retrospective
evaluation of the clinical and radiographic risk factors associated
with severe pulmonary hemorrhage in first-line advanced,
unresectable non-small-cell lung cancer treated with carboplatin
and paclitaxel plus bevacizumab. J Clin Oncol. 27:1405–1412. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Y, Huang X, Jiang J, Hu W, Hu J, Cai J,
Rong X, Cheng J, Xu Y, Wu R, et al: Clinical variables for
prediction of the therapeutic effects of bevacizumab monotherapy in
nasopharyngeal carcinoma patients with radiation-induced brain
necrosis. Int J Radiat Oncol Biol Phys. 100:621–629. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Furuse M, Nonoguchi N, Kawabata S,
Yoritsune E, Takahashi M, Inomata T, Kuroiwa T and Miyatake S:
Bevacizumab treatment for symptomatic radiation necrosis diagnosed
by amino acid PET. Jpn J Clin Oncol. 43:337–341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhuang H, Shi S, Yuan Z and Chang JY:
Bevacizumab treatment for radiation brain necrosis: Mechanism,
efficacy and issues. Mol Cancer. 18:212019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Furuse M, Kawabata S, Kuroiwa T and
Miyatake SI: Repeated treatments with bevacizumab for recurrent
radiation necrosis in patients with malignant brain tumors: A
report of 2 cases. J Neurooncol. 102:471–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taugourdeau-Raymond S, Rouby F, Default A
and Jean-Pastor MJ; French network of pharmacovigilance centers, :
Bevacizumab-induced serious side-effects: A review of the French
pharmacovigilance database. Eur J Clin Pharmacol. 68:1103–1107.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tijtgat J, Calliauw E, Dirven I, Vounckx
M, Kamel R, Vanbinst AM, Everaert H, Seynaeve L, Van Den Berge D,
Duerinck J and Neyns B: Low-dose bevacizumab for the treatment of
focal radiation necrosis of the brain (fRNB): A single-center case
series. Cancers (Basel). 15:25602023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao M, Wang X, Wang X, Niu G, Liu X, Zhao
S, Wang Y, Yu H, Huo S, Su H, et al: Can low-dose intravenous
bevacizumab be as effective as high-dose bevacizumab for cerebral
radiation necrosis? Cancer Sci. 115:589–599. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhuang H, Zhuang H, Shi S and Wang Y:
Ultra-low-dose bevacizumab for cerebral radiation necrosis: A
prospective Phase II clinical study. Onco Targets Ther.
12:8447–8453. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dashti SR, Kadner RJ, Folley BS, Sheehan
JP, Han DY, Kryscio RJ, Carter MB, Shields LBE, Plato BM, La Rocca
RV, et al: Single low-dose targeted bevacizumab infusion in adult
patients with steroid-refractory radiation necrosis of the brain: A
phase II open-label prospective clinical trial. J Neurosurg.
137:1676–1686. 2022. View Article : Google Scholar : PubMed/NCBI
|
